Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
PsiOxus Therapeutics Ltd.
About
  2. Companies
  3. PsiOxus Therapeutics Ltd.
  4. Products
  5. PsiOxus - Model NG-347 - Single or ...

PsiOxus - Model NG-347 - Single or Multi-Protein Therapeutics Medicine

SHARE

Three transgenes: Producing membrane bound CD80 and secreted MIP1α and IFNa. As part of our expanding T-SIGn platform pipeline, this candidate is progressing through its IND enabling activities in readiness for entering clinical trials.

Most popular related searches
protein therapeutic
clinical trial
intravenous injectable
immuno-oncology
viral vector
therapeutic potential
intravenous injection
tumor microenvironment
T-cell
cancer treatment

Our approach to treating cancer involves selective delivery of single or multi-protein therapeutics to tumors via an intravenously injected viral vector. These therapeutics act locally to reprogram the tumor microenvironment, providing new treatment options for patients with cancer.

Our novel class of medicines expand the potential of immunotherapy to applications beyond T cell-rich ‘hot’ tumors, with therapeutic potential as both single agent and in combination with current immuno-oncology agents